After generating the SMAD4‐modulated gene profile using data from the discovery cohort, we assessed whether this gene profile could be used to identify CRC patients at risk of recurrent disease and corresponding worse outcomes. This evidence concerns the gene SMAD4 and colorectal carcinoma.